| Objective:DetectingChronic hepatitis B(Chronic hepatitis B,CHB)blood circulation in patients with soluble T lymphocyte immune globulin sticky protein molecule-3(sTIM-3)and Gamma interferon(IFN-γ)expression level,to investigate the changes of sTIM-3 and IFN-γ in circulating blood during anti-HBV treatment in patients with chronic hepatitis B,learn more about the correlation between HBV-DNA,ALT,AST and TBIL with sTIM-3 and IFN-γ,to understand the correlation between sTIM-3 and IFN-y,and To investigate the correlation of sTIM-3 with hepatitis B virus(HBV).Methods:Selecteing 150 cases of primary accept entecavir treatment of CHB patients for follow-up object,follow-up of 24 weeks of 101 cases,the people that will be followed up to 24 weeks of patients as treatment group.At the same time,choosing the same period in our hospital in 25 healthy physical examination as the control group,in the same period in our hospital outpatient clinic or hospital treatment of hepatitis B cirrhosis 20 cases,20 patients with hepatitis B liver failure as control subjects.Collection of CHB patients magicyang peripheral venous blood serum on an empty stomach before treatment and the 12th,the 24th treatment,using the method of enzyme-linked immunosorbent(ELISA)detecte expression level of circulating blood sTIM-3 and IFN-y in patients with CHB,using the method of real TIMe fluorescence quantitative detecte of HBV-DNA loads,using the method of chemiluminescence detecte infection markers of hepatitis B virus,applying the brake biochemical analyzer test liver function index.In the control group,circulating blood sTIM-3,IFN-y and HBV-DNA,ALT,AST and TBIL were detected in the same way as in CHB patients.Operating by hand according to the reagent instructions.Results:1.At the 12th week of ETV anti-HB V treatment,the expression levels of ALT,AST and TBIL in circulating blood and HBV-DNA loads in CHB group significantly decreased compared with that before treatment(P<0.05).At 24 weeks of treatment,HBV-DNA loads and ALT values in the CHB group were lower than the lower limit of the reference value.2.Before treatment,the expression level of stim-3 in the circulating blood of patients in the CHB group was higher than that of healthy patients and those in the hepatitis b cirrhosis group(P<0.05),and lower than that of patients with hepatitis B liver failure(P>0.05).The expression level of IFN-y in the circulating blood of the CHB group was lower than that of the healthy subjects and the hepatitis B cirrhosis group(P<0.05).The expression level of IFN-y in the circulating blood of the CHB group was higher than that of the hepatitis B liver failure group(P<0.05).STIM-3 and IFN-γ levels in circulating blood before treatment were significantly different in the four groups(F=20.94,P=0.00;F=103.20,P=0.00).3.CHB patients with before treatment blood circulation sTIM-3 level is relatively higher expression than the healthy check-up group(P<0.05).After 12 weeks of treatment,CHB group sTIM-3 level is relatively the healthy check-up group,there was no significant difference(P>0.05).After 12 weeks of treatment,CHB group sTIM-3 levels are lower expression before treatment(P<0.05),After 24 weeks of treatment,CHB group sTIM-3 level continues to decline,there was no significant difference with After 12 weeks of treatment(P>0.05).IFN-y in circulating blood of CHB group was lower than that of healthy subjects before treatment(P<0.05),IFN-y in CHB group was higher after 12 weeks of treatment(P<0.05),and IFN-y in CHB group was higher after 24 weeks of treatment than at 12 weeks of treatment(P<0.05).After 24 weeks of treatment,there was no significant difference in IFN-y syndrome level between CHB group and the healthy subj ects(P>0.05).4.Before treatment,the level of sTIM-3 in CHB patients gradually increased with the aggravation of the disease degree.The expression level of sTIM-3 in the moderate and severe CHB groups was significantly higher than that in the mild group(P<0.05).The level of sTIM-3 in the three groups of CHB patients was significantly higher than that in the mild group(F=724.74,P=0.00).Before treatment,IFN-ylevel in CHB patients was significantly down-regulated with the aggravation of the disease degree,and the expression level of IFN-y in the moderate and severe CHB groups was significantly down-regulated compared with that in the mild group(P<0.05).The level of IFN-y in the three groups of CHB patients was significantly different(F=285.34,P=0.00).After 24 weeks of anti-HBV treatment,sTIM-3 expression levels in the CHB group were significantly lower in the mild,moderate and severe groups than before treatment(P<0.05).The expression level of IFN-γin the mild group,the moderate group and the severe group was significantly up-regulated compared with that before treatment(P<0.05;F=99.34,P=0.00).5.Before treatment,HBV-DNA in CHB group was positively correlated with ALT,AST and TBIL(r=0.266,p=0.007;r=0.277,P=0.005;r=0.231,P=0.020);Before treatment,ALT,AST and TBIL in CHB group were positively correlated(r=0.981,P=0.000;r=0.890,P=0.000);AST and TBIL were positively correlated in CHB group before treatment(r=0.902,P=0.000).There was no correlation between circulating HBV-DNA and ALT,AST and TBIL in CHB group after 24 weeks of treatment.6.Before treatment,the expression level of circulating sTIM-3 in CHB group was negatively correlated with the expression level of IFN-γ(r=-0.853,P=0.000).After 24thof treatment,the expression level of circulating sTIM-3 in CHB group was negatively correlated with the level of IFN-yexpression(r=-0.447,P=0.000).7.Before treatment,the expression level of circulating sTIM-3 in CHB group was positively correlated with the amount of HBV-DNA and the levels of ALT,AST and TBIL(r=0.276,P=0.005;r=0.949,P=0.000;r=0.956,P=0.000;r=0.890,P=0.000);Before treatment,circulating IFN-γ was negatively correlated with ALT、AST and ALT levels in CHB group(r=-0.787,r=-0.786,r=-0.773,P=0.000),while IFN-γ was not correlated with lghbv-dna load(r=-0.087,P=0.388).After 24 weeks of treatment,the expression level of circulating sTIM-3 in CHB group was positively correlated with TBIL(r=0.232,P=0.020).There was no correlation between sTIM-3 expression level and ALT,AST and HBV-DNA load(r=-0.177,P=0.077;r=0.169,P=0.092;r=0.080,P=0.426);There was a negative correlation between the level of circulating IFN-yin the CHB group and the level of AST(r=-0.225,P=0.024).There was no correlation between ALT and TBIL expression levels and HBV-DNA load(r=0.077,P=0.446;r=-0.178,P=0.06 1,r=-0.184,P=0.066).8.Before treatment,the expression levels of sTIM-3 and IFN-y in the circulating blood gradually increased and decreased with the aggravation of the disease course of CHB patients.The expression level of sTIM-3 was positively correlated with the severity of CHB(r=0.787,P=0.000),while the expression level of IFN-y was negatively correlated with the severity of CHB(r=-0.741，P=0.000).Conclusion:1.The HBV-DNA load and the degree of inflammation in the circulating blood of CHB patients were positively correlated with the level of sTIM-3 and negatively correlated with the level of IFN-γ.There was a negative correlation between sTIM-3 and IFN-y level.2.The level of sTIM-3 in the circulating blood of CHB patients is positively correlated with the degree of the patient’s disease,and the level of IFN-yis negatively correlated with the degree of the patient’s disease,suggesting that sTIM-3 may weaken the clearance of HBV-DNA by inhibiting the release of IFN-y,leading to chronic HBV infection.3.The expression level of sTIM-3 in circulating blood of CHB patients can be used as a potential indicator of liver injury. |
PDF Full Text Request